PUBLICATIONS
SELECTED PUBLICATIONS
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. Knopf P, Stowbur D, Hoffmann SHL, Hermann N, Maurer A, Bucher V, Poxleitner M, Tako B, Sonanini D, Krishnamachary B, Sinharay S, Fehrenbacher B, Gonzalez-Menendez I, Reckmann F, Bomze D, Flatz L, Kramer D, Schaller M, Forchhammer S, Bhujwalla ZM, Quintanilla-Martinez L, Schulze-Osthoff K, Pagel MD, Fransen MF, Röcken M, Martins AF, Pichler BJ, Ghoreschi K, Kneilling M.
Mol Cancer. 2023 Dec 15;22(1):207. doi: 10.1186/s12943-023-01900-0.
A replicating LCMV-based vaccine for the treatment of solid tumors. Purde MT, Cupovic J, Palmowski YA, Makky A, Schmidt S, Rochwarger A, Hartmann F, Stemeseder F, Lercher A, Abdou MT, Bomze D, Besse L, Berner F, Tüting T, Hölzel M, Bergthaler A, Kochanek S, Ludewig B, Lauterbach H, Orlinger KK, Bald T, Schietinger A, Schürch C, Ring SS, Flatz L. A
Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma. Nübel C, Amaral T, Leiter U, Flatz L, Forschner A.
Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study. Wagner NB, Knierim SM, Luttermann F, Metzler G, Yazdi AS, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler TK, Forchhammer S, Flatz L.
J Am Acad Dermatol. 2023; doi:10.1016/j.jaad.2023.11.040
Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients. Lichtensteiger, C., Koblischke, M., Berner, F., Jochum, A-K., Sinnberg, T., Balciunaite, B., ... [et al].
Journal of Autoimmunity (2023). doi: https://doi.org/10.1016/j.jaut.2023.103118
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. Wagner NB, Lenders MM, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler TK, Flatz L.
Eur J Cancer. 2024;196:113425. doi:10.1016/j.ejca.2023.113425
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. Amaral T, Pop OT, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring SS, Joerger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Holzel M, Dummer R, Schurch CM, Forschner A, Flatz L.
Journal of the American Academy of Dermatology. 2023 doi: https://doi.org/10.1016/j.jaad.2023.06.057
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. 2023.
Nat Cancer (2023). doi: https://doi.org/10.1038/s43018-023-00610-2
Autoimmunity in immune checkpoint inhibitor‐induced immune‐related adverse events: A focus on autoimmune skin toxicity and pneumonitis. Berner F, Flatz L.
Immunol Rev. 2023. doi:10.1111/imr.13258
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Nuñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L.
Med. 2023. doi: 10.1016/j.medj.2022.12.007
Pulmonary surfactant proteins are inhibited by IgA autoantibodies in severe COVID-19. Sinnberg T, Lichtensteiger C, Hasan Ali O, Pop OT, Jochum AK, Risch L, Brugger SD, Velic A, Bomze D, Kohler P, Vernazza P, Albrich WC, Kahlert CR, Abdou MT, Wyss N, Hofmeister K, Niessner H, Zinner C, Gilardi M, Tzankov A, Röcken M, Dulovic A, Shambat SM, Ruetalo N, Buehler P, Scheier TC, Jochum W, Kern L, Henz S, Schneider T, Kuster GM, Lampart M, Siegemund M, Bingisser R, Schindler M, Schneiderhan-Marra N, Kalbacher H, McCoy KD, Spengler W, Brutsche MH, Macek B, Twerenbold R, Penninger JM, Matter MS, Flatz L.
Am J Respir Crit Care Med. 2022 Aug 4. doi: 10.1164/rccm.202201-0011OC.
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann LK, Marcu A, Wolfschmitt EM, Haen S, Gross T, Abdou MT, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng HW, Toma M, Klümper N, Purde MT, Pop OT, Jochum AK, Pascolo S, Joerger M, Früh M, Jochum W, Rammensee HG, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L.
Sci Immunol. 2022 Sep 2; 7(75):eabn9644. doi: 10.1126/sciimmunol.abn9644.
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
Klümper N, Saal J, Berner F, Lichtensteiger C, Wyss N, Heine A, Bauernfeind FG, Ellinger J, Brossart P, Diem S, Schmid S, Joerger M, Frueh M, Ritter M, Hölzel M, Flatz L, Bald T.
J Immunother Cancer. 2022 Mar;10(3):e004024. doi: 10.1136/jitc-2021-004024.
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.
Yurchenko AA, Pop OT, Ighilahriz M, Padioleau I, Rajabi F, Sharpe HJ, Poulalhon N, Dreno B, Khammari A, Delord M, Alberti A, Soufir N, Battistella M, Mourah S, Bouquet F, Savina A, Besse A, Mendez-Lopez M, Grange F, Monestier S, Mortier L, Meyer N, Dutriaux C, Robert C, Saiag P, Herms F, Lambert J, de Sauvage FJ, Dumaz N, Flatz L, Basset-Seguin N, Nikolaev SI.
Clin Cancer Res. 2022 Apr 1;28(7):1422-1432. doi: 10.1158/1078-0432.CCR-21-3764.
Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment.
Ring SS, Cupovic J, Onder L, Lütge M, Perez-Shibayama C, Gil-Cruz C, Scandella E, De Martin A, Mörbe U, Hartmann F, Wenger R, Spiegl M, Besse A, Bonilla WV, Stemeseder F, Schmidt S, Orlinger KK, Krebs P, Ludewig B, Flatz L.
Nat Commun. 2021 Aug 5;12(1):4734. doi: 10.1038/s41467-021-25057-w.
Berner F, Niederer R, Luimstra JJ, Pop OT, Jochum AK, Purde MT, Hasan Ali O, Bomze D, Bauer J, Freudenmann LK, Marcu A, Wolfschmitt EM, Haen S, Gross T, Dubbelaar ML, Abdou MT, Baumgaertner P, Appenzeller C, Cicin-Sain C, Lenz T, Speiser DE, Ludewig B, Driessen C, Jörger M, Früh M, Jochum W, Cozzio A, Rammensee HG, Walz J, Neefjes J, Flatz L.
Oncoimmunology. 2021 Nov 27;10(1):2006893. doi: 10.1080/2162402X.2021.2006893.
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Purde MT, Niederer R, Wagner NB, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Joerger M, Risch M, Niederhauser C, Lenz TL, Früh M, Risch L, Semela D, Flatz L.
J Cancer Res Clin Oncol. 2021 Dec 7. doi: 10.1007/s00432-021-03870-6.
Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge.
Krolik M, Csepregi L, Hartmann F, Engetschwiler C, Flatz L.
Vaccine. 2021 Feb 22;39(8):1257-1264. doi: 10.1016/j.vaccine.2021.01.047.
Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8+ T Cell Responses.
Ring SS, Królik M, Hartmann F, Schmidt E, Ali OH, Ludewig B, Kochanek S, Flatz L.
Mol Ther Oncolytics. 2020 Oct 10;19:179-187. doi: 10.1016/j.omto.2020.10.001.
Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies.
Hasan Ali O, Bomze D, Risch L, Brugger SD, Paprotny M, Weber M, Thiel S, Kern L, Albrich WC, Kohler P, Kahlert CR, Vernazza P, Bühler PK, Schüpbach RA, Gómez-Mejia A, Popa AM, Bergthaler A, Penninger JM, Flatz L.
Clin Infect Dis. 2020 Sep 30:ciaa1496. doi: 10.1093/cid/ciaa1496.
Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.
Hasan Ali O, Berner F, Ackermann CJ, Ring SS, Moulin A, Müller J, Markert E, Pop OT, Müller S, Diem S, Hundsberger T, Flatz L.
Cancer Immunol Immunother. 2021 Feb;70(2):563-568. doi: 10.1007/s00262-020-02693-7.
Genomic profiling of late-onset basal cell carcinomas from two brothers with nevoid basal cell carcinoma syndrome.
Hasan Ali O, Yurchenko AA, Pavlova O, Sartori A, Bomze D, Higgins R, Ring SS, Hartmann F, Bühler D, Fritzsche FR, Jochum W, Navarini AA, Kim A, French LE, Dermitzakis E, Christiano AM, Hohl D, Bickers DR, Nikolaev SI, Flatz L.
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):396-402. doi: 10.1111/jdv.16767.
BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors.
Hasan Ali O, Bomze D, Ring SS, Berner F, Fässler M, Diem S, Abdou MT, Hammers C, Emtenani S, Braun A, Cozzio A, Mani B, Jochum W, Schmidt E, Zillikens D, Sadik CD, Flatz L.
J Am Acad Dermatol. 2020 Apr;82(4):854-861. doi: 10.1016/j.jaad.2019.08.045.
Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden.
Bomze D, Hasan Ali O, Bate A, Flatz L.
JAMA Oncol. 2019 Aug 22;5(11):1633-5. doi: 10.1001/jamaoncol.2019.3221.
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, Cruz CG, van de Veen W, Akdis M, Nikolaev S, Läubli H, Zippelius A, Hartmann F, Cheng HW, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy AN, Jochum W, Speiser DE, Flatz L.
JAMA Oncol. 2019 Jul 1;5(7):1043-1047. doi: 10.1001/jamaoncol.2019.0402.
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.
Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Del Carmen Gil Cruz C, Pérez Shibayama CI, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser DE, Ludewig B, Levesque MP, Dummer R, Flatz L.
J Immunother Cancer. 2019 Feb 20;7(1):50. doi: 10.1186/s40425-019-0523-2.
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.
Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, Jörger M, Früh M, Driessen C, Lenz TL, Flatz L.
Eur J Cancer. 2019 Jan;107:8-14. doi: 10.1016/j.ejca.2018.11.009.
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment.
Diem S, Fässler M, Bomze D, Ali OH, Berner F, Niederer R, Hillmann D, Mangana J, Levesque MP, Dummer R, Risch L, Recher M, Risch M, Flatz L.
J Immunother. 2019 Apr;42(3):89-93. doi: 10.1097/CJI.0000000000000255.
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment.
Diem S, Fässler M, Hasan Ali O, Siano M, Niederer R, Berner F, Roux GA, Ackermann CJ, Schmid S, Güsewell S, Früh M, Flatz L.
Cancer Manag Res. 2018 Nov 8;10:5537-5544. doi: 10.2147/CMAR.S179767.